Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma-Reference-Cited by-同舟云学术

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

Published:2024-09-05 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Parrondo Ricardo D.^ORCID,LaPlant Betsy R.,Elliott Jamie,Fernandez Andre,Flott Caitlin J.,Arrington Diedre,Chapin Dustin,Brown Jade,Das Saurav^ORCID,Roy Vivek^ORCID,Chanan-Khan Asher A.,Ailawadhi Sikander^ORCID

Funder

Mayo Clinic Cancer Center, Department of Hematology Oncology

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01134-3.pdf

Reference16 articles.

1. Joseph NS, Kaufman JL, Dicamillo S, Roberts D, Gupta VA, Hofmeister CC, et al. Comparison of response and survival outcomes in standard- and high-risk newly diagnosed transplant-eligible multiple myeloma (NDMM) patients treated with lenalidomide, bortezomib and dexamethasone (RVD) versus daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD). Blood. 2023;142:647.

2. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62:1841–9.

3. Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10:91.

4. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–31.

5. Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811–22.